BioCryst (BCRX) Turns First Profit, CEO Eyes Rare-Disease Acquisition Push

Existing holders of BioCryst Pharmaceuticals (NASDAQ: BCRX) added to positions in the second quarter without new funds entering, pushing combined hedge fund position value to $867 million from $756 million on a flat count of 46 firms. That concentration arrived alongside the company's first turn to profitability, with Orladeyo guiding up to $645 million in 2026 sales and CEO Charlie Gayer declaring an acquisition push for more rare disease assets. Navenibart's late-stage trial data, expected in 2027, is the next event that can justify or stress the positioning.

The numbers in focus

Orladeyo, a hereditary angioedema treatment, is the primary revenue and cash-generation engine. BioCryst guided up to $645 million in 2026 sales for the drug, per company statements, and Gayer, who took the chief executive role in January, said the firm expects to grow profits each year without needing to raise outside capital. The January acquisition of Astria Therapeutics brought navenibart, a late-stage hereditary angioedema candidate, into the pipeline. That asset completed enrollment in its trial in June, with data expected in 2027.

BioCryst also rationalized its European exposure. The company sold its European Orladeyo business to Neopharmed Gentili for $250 million upfront in 2025, then licensed European navenibart rights to a Neopharmed affiliate for $70 million upfront, up to $275 million in regulatory and sales milestones, and royalties of 18% to 30% on net sales. That structure lets BioCryst focus on its U.S. business while keeping economic participation in navenibart's potential European performance.

What the balance sheet says about the setup

The profitability headline is real, and the balance sheet context complicates it. BioCryst carries roughly $822 million in combined term-loan and royalty obligations and reports negative shareholders' equity. The Astria deal alone triggered a $697.8 million non-cash charge for acquired in-process research and development.

Consensus is pricing this as a rerating story: one profitable drug funds the next deal, navenibart adds a second hereditary angioedema asset, and management builds a diversified rare-disease franchise without constant dilution. The pressure point is that Orladeyo has to keep delivering to service $822 million in obligations and fund future acquisitions at the same time. The concentrated book of existing holders, with no new funds visible in the second-quarter count, means there are fewer incremental buyers available if patient growth slows or a deal misfires. Navenibart data in 2027 is what to watch.

Related reading

• Vera Bradley Q2 2027: direct channel momentum and balance sheet repair signal Project Sunshine progress
• AI executives call for oversight, and the crowded side of that trade deserves a look
• Five Dividend Aristocrats in focus as guidance raises reinforce multi-decade income streaks